Exact Sciences (EXAS) Tops Q2 EPS by 8c, Sales Beat; Raises Cologuard Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Exact Sciences (EXAS) PT Raised to $45 at Canaccord Genuity Following 2Q
July 26, 2017 10:11 AM EDTCanaccord Genuity raised its price target on Exact Sciences (NASDAQ: EXAS) to $45.00 (from $42.00) while maintaining a Buy rating. 2Q revenues of $57.6M came in ahead of the Street's $49.7M. EXAS holds $483M of cash and Cologuard is now covered by 235M... More
